Fresenius Medical Care (NYSE: FMS) appointed Helen Giza as CEO, recently, a month after the company cut its outlook in 2022 and it was reported that the investor Elliott Investment Management had a 3% stake. the company.
Giza, former deputy CEO and currently CFO, replaces Carla Kriwet, who is leaving the company voluntarily and mutually due to serious differences, Fresenius said in a press release on Tuesday.
“This company has great potential and is about to make a big change,” Kriwet said.
Giza will also be a member of the Management Board of Fresenius Management SE. Meanwhile, Kriwet has also resigned from this position.
“In the best companies Fresenius Medical Care now has to increase its focus on operational improvements, improve operations, and focus on the core,” said Michael Sen, chairman of the Fresenius Medical Care Management AG Supervisory Board and CEO of Fresenius. SE.
At the end of October, FMS cut its 2022 interest rate amid lower prices and lower than expected North American business.
Separately, it was revealed that private equity investor Elliott had taken over a German dialysis provider and the company believed that a structural change was necessary.
FMS images -0.80% to $16.08 in pre-sale on Dec. 6